首页> Clinical lung cancer> Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.

Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.

导出原文传递

翻译打印收藏纠错

第一作者： Petra,Martin

第一单位： Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

作者： Petra,Martin ^[1] ; Erin,Stewart ^[2] ; Nhu-An,Pham ^[3] ; Celine,Mascaux ^[1] ; Devang,Panchal ^[3] ; Ming,Li ^[3] ; Lucia,Kim ^[3] ; Shingo,Sakashita ^[4] ; Dennis,Wang ^[3] ; Jenna,Sykes ^[3] ; Thomas,Friess ^[5] ; Frances A,Shepherd ^[1] ; Geoffrey,Liu ^[1] ; Ming-Sound,Tsao ^[6]

作者单位： Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada. ^[1] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. ^[2] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. ^[3] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. ^[4] Department of Pharmacology, Roche Diagnostics GmbH, Mannheim, Germany. ^[5] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address: Ming.Tsao@uhn.ca. ^[6]

关键词 Cancer EGFR Ligand NSCLC Signaling